DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20173276

A prospective study of efficacy and safety of olopatadine versus azelastine in allergic conjunctivitis at a tertiary care hospital

Jayanthi C. R., Nanthini R., . Vijayalakshmi

Abstract


Background: Allergic conjunctivitis, an ocular surface inflammatory disease with significant social and economic impact affects approximately 25% of the general population. H1 receptor blockers, mast cell stabilizers and drugs that block cytokine and prostaglandin formation form the treatment armamentarium. Olopatadine hydrochloride and Azelastine hydrochloride are dual-acting selective H1 receptor antagonist with mast-cell stabilizing property. This study was undertaken to assess the efficacy and safety of olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% in allergic conjunctivitis amongst Indians.

Methods: After obtaining Institutional Ethics Committee approval and written informed consent, 120 patients diagnosed with allergic conjunctivitis fulfilling the inclusion/exclusion criteria were enrolled in the study. Study was done from April 2014 to June 2015 at Minto eye hospital. Study subjects were treated with olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% eye drops BD for 15 days. Ocular symptoms, instead of and signs and adverse events, if any were recorded on the day 8 and day 15 follow up visits.

Results: At the end of the study period, the reduction in the ocular itching score from baseline was higher in the olopatadine group compared to the azelastine group (p<0.002). Similarly, the scores of ocular congestion (p<0.008), foreign body sensation (p<0.009), tearing (p<0.001), erythema (p<0.002) and chemosis (p<0.015) also showed larger reduction in the olopatadine treated patients. The common adverse events encountered in both the groups were stinging after instillation, burning, bitter taste and headache.

Conclusions: In allergic conjunctivitis, both olopatadine and azelastine were found to be effective in relieving ocular signs and symptoms, but olopatadine was found to be superior in terms of efficacy, safety and tolerability with minimal side effects.


Keywords


Allergic conjunctivitis, Azelastine hydrochloride 0.05% eye drops, Olopatadine hydrochloride 0.1% eye drops

Full Text:

PDF

References


Uchio E. Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clinical Ophthalmology. 2008;2(3):525-31.

Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW, Bron AJ. Economic and quality of life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol. Feb 2004;11(1):17-33.

Smith AF, Pitt AD, Rodruiguez AE, Alio JL, Marti N, Teus M. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol. Aug 2005;12(4):233-42.

Irani AM, Butrus SI, Tabbara KF, Schwartz LB. Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol. 1990;86:34-40.

Leonardi A. The role of histamine in allergic conjunctivitis. Acta Ophthalmol Scand. 2000;230:18-21.

Kidd M, McKenzie SH, Steven I, Cooper C, Lanz R. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br J Ophthalmol. Oct 2003;87(10):1206-11.

Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs. 2005;65(2):21528.

Ohmori K. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride: a new anti-allergic drug. Jpn J Pharmacol. 2002;88:379-97.

Ciprandi G, Cosentino C, Milanese M, Tosca MA. Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions. Ann Allergy Asthma Immunol. 2003;90:434-8.

Reddy MS, Suneetha N, Thomas RK, Battu RR. Topical diclofenac sodium for treatment of postoperative inflammation in cataract surgery. Indian journal of ophthalmology. 2000;48(3):223-6.

Yaylali V, Demirlenk I, Tatlipinar S, Ozbay D, Esme A, Yildirim C, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol. Scand. 2003;81:378-82.

Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11:471.

Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther. 2001 Aug;23(8):1272-80.

Sánchez MC, Parra BF, Matheu V, Navarro A, Ibáñez MD, Dávila I, et al. Allergic conjunctivitis (SEAIC Rhinoconjuntivitis Committee 2010). J Investig Allergol Clin Immunol. 2011;21(2):1-19.

Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol. 2010;126(4):778.

John J, Ahmed S, Anjum F, Kebab M, Mohammed N, Darwich H. Prevalence of Allergies among University Students: A Study from Ajman, United Arab Emirates. ISRN Allergy. 2014:502052.

Abokyi S, Koffuor G, Ntodie M, Kyei S, Gyanfosu L. Epidemiological profile and pharmacological management of allergic conjunctivitis: A study in Ghana. Int J Pharm. 2012;3(4):195-201.

Peate WF. Work-Related Eye Injuries and Illnesses. Am Fam Physician 2007;75:1017-22.

Njinaka I, Uhumwangho M, Edema TO, Dawodu OA, Omoti AE. A Comparison Study of Conjunctiva Disorders in Technical and Administrative Sawmill Workers in Nigeria. Malaysian J Med Sci. 2011;18(3):43-8.

Lois N, Abdelkader E, Reglitz K, Garden C, Ayres J G. Environmental tobacco smoke exposure and eye disease. Br J Ophthalmol. 2008;92(10):1304-10.

Shubhrica. Effect of Environment on Eyes: A Review. Indian Journal of Clinical Practice. Sept 2013;24(4):381-4.

Epstein AB, Hoven TV, Kaufman A, Carr W. Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clin Ophthalmol. 2009;3:329-36.

Oliva AM, Slonim CB. Patient Evaluation of Azelastine HCl versus Olopatadine HCl in the Treatment of Allergic Conjunctivitis. Investigative Ophthalmology and Visual Science. May 2005;46:937.

Abelson MB, Loeffler O. Conjunctival allergen challenge: models in the investigation of ocular allergy. Curr Allergy Asthma Rep. 2003;3:363-8.

Brockman HL, Momsen MM, Knudtson JR, Miller ST, Graff G, Yanni JM. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm. 2003;11(4):247-68.